2 Response Genetics Analyst Ratings, Earnings, Dividends and Insider Trades | $RGDX | NASDAQ:RGDX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Response Genetics Company Profile (NASDAQ:RGDX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Response Genetics (NASDAQ:RGDX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)Consensus Rating:Buy (Score: 2.67)Consensus Price Target: $2.65 (82.76% upside) Analysts' Ratings History for Response Genetics (NASDAQ:RGDX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare9/2/2013ZacksDowngradeOutperform -> Neutral$2.60View 8/8/2013Ladenburg ThalmannBoost Price TargetBuy$1.75 -> $2.75View 7/15/2013ZacksUpgradeNeutral -> Outperform$1.80View 3/15/2013Roth CapitalInitiated CoverageBuy$2.60View 11/14/2012Ladenburg ThalmannUpgradeNeutral -> Buy$1.75View (Data available from 3/11/2012 forward) Earnings History for Response Genetics (NASDAQ:RGDX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/7/2013Q313($0.07)($0.08)$5.40 million$4.10 millionViewN/AView 8/8/2013Q2 2013($0.04)($0.11)$5.40 million$5.30 millionViewN/AView 5/14/2013Q1 2013($0.04)($0.03)$4.92 million$5.60 millionViewN/AView 11/13/2012Q312($0.07)($0.05)$4.50 million$5.40 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Response Genetics (NASDAQ:RGDX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Response Genetics (NASDAQ:RGDX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare12/23/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell134,991$1.11$149,840.01View 12/19/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell135,666$1.18$160,085.88View 12/16/2013Austin W & Greenhouse Da MarxeMajor ShareholderSell353,677$1.17$413,802.09View 11/27/2012Austin W & Greenhouse Da MarxeMajor ShareholderBuy463,278$1.02$472,543.56View (Data available from 1/1/2013 forward) About Response Genetics Response Genetics, Inc. focuses on providing molecular profiling services of tumor tissue that has been formalin-fixed and embedded in paraffin wax. The Company focuses on the commercialization of the ResponseDX tests. It is developing additional diagnostic tests for assessing the risk of cancer recurrence, prediction of chemotherapy response and tumor classification in cancer patients. The Company is expanding the pharmacogenomic testing services business into and creating an integrated testing platform for the healthcare industry. Headlines: (3/10) Response Genetics, Inc. to Offer Expanded KRAS Mutation Test to Improve Treatment Decisions for Colorectal Cancer ... (3/10) InPlay from Briefing.com Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: RGDX CUSIP: Key Metrics: Previous Close: $1.3950 Day Moving Average: $1.4359200 Day Moving Average: $1.6768 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $49.7MCurrent Quarter EPS Consensus Estimate: $-0.21 EPS Additional Links: View RGDX on Google FinanceView RGDX on Yahoo FinanceView RGDX's Company Profile on ReutersSearch for Response Genetics on Google Response Genetics (NASDAQ:RGDX) Chart for Tuesday, March, 11, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.